Topics

Risk of SDRs Under 3HP and 1HP Regimen for LTBI

2019-09-24 05:27:37 | BioPortfolio

Summary

Successful implement of preventive therapy for subjects with latent tuberculosis infection (LTBI) is the critical step for elimination of tuberculosis (TB). The major obstacle of traditional preventive therapy is the unacceptable long treatment duration, taking isoniazid 5mg/kg daily for a total of 9 months (9H), thus seriously compromising its acceptability. With the introduction of 12-doses weekly high-dose (15 mg/kg) rifapentine plus isoniazid (3HP regimen), the completion rate of 3HP has be shown to be much higher than 9H. However, 4.9% to 9.1% of LTBI cases who received 3HP failed to complete treatment because of side effects. Systemic drug reactions (SDRs), even hypotension and shock, under 3HP treatment are higher than 9H treatment.

A recent study in HIV patients demonstrated that a new short-term regimen, consisting of isoniazid 5mg/kg plus rifapentine 10mg/kg daily for one month (1HP), has a similar risk of adverse reactions as 3HP. Clinical study with head-to-head comparison between 3HP and 1HP, however, remains lacking.

The prospective multicenter study is conducted to investigate whether risk of SDRs under 1HP is lower than that under 3HP.

Hypothesis: 1HP has a lower incidence rate of SDRs than 3HP

Objectives:

1. To compare the risk of SDRs in 1HP treatment and in 3HP treatment

2. To explore side effect profile of 1HP

Methods:

This multicenter randomized control trial will compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP), and a new regimen consisting of daily rifapentine (10 mg/kg) plus isoniazid (5 mg/kg) for 1 month (Arm 2: 1HP).

Description

Tuberculosis (TB) remains one of the deadliest infectious diseases, with an estimated 10.0 million new cases and 1.6 million deaths in 2017. The World Health Organization (WHO) has set the goal of eliminating TB as a public health problem, aiming to achieve 90% and 95% reductions in the TB incidence and number of TB deaths by 2035. Latent tuberculosis infection (LTBI), a status of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without clinically manifest active TB, has a 10% risk of progressing to active TB and has thus emerged as a critical target for improving TB control and elimination.

The effectiveness of LTBI programmes has long been limited. In 1999, real-world data obtained from an inner-city population in Atlanta, Georgia in the United States revealed that only 27% of subjects receiving isoniazid (INH) preventive therapy completed their treatment. A 2016 meta-analysis including 748,572 subjects in 58 studies also found poor completion of LTBI programmes, with a 60% treatment completion rate. With the introduction of rifapentine (RPT), a rifamycin with much longer half-life than rifampin, the duration of a modern preventive regimen termed 3HP comprising RPT and INH could be shortened to 12 doses administered weekly, with the completion rate approaching 90%. However, 3.8% of those receiving 3HP experience systemic drug reactions (SDRs). The risks of severe adverse event (AE) and SDRs are even higher among subjects >35 years old.

To date, little has been discovered regarding the risk factors or predictors of SDRs due to 3HP therapy. In a pharmacokinetics study of once-weekly RPT treatment in 35 TB patients during continuation phase therapy, serious AEs were not linked with a higher area under the plasma concentration-time curve (AUC0~∞) of RPT. Furthermore, no studies have reported on plasma INH levels after once-weekly INH treatment or the association between plasma INH level and AE development. Under the support of the Taiwan Centers for Disease Control (TCDC), a prospective multicenter observational study was conducted in Taiwan since 2016 to investigate the correlation between SDRs and plasma concentrations of INH, RPT and their major metabolites - acetyl-isoniazid (AcINH) and desacetyl-rifapentine (DeAcRPT). Preliminary results from 129 LTBI cases showed that those with SDRs and those without SDRs had similar plasma concentrations of the 4 compounds at either post-dose 6 or 24 hours (C6 or C24), except that the C24 plasma INH concentration was significantly higher in the SDRs group. Furthermore, generalised estimating equation (GEE) model revealed that C24 plasma INH level was associated with a higher risk of SDR development (OR [95% CI]: 1.61 [1.15-2.25], p = 0.006). By contrast, C24 plasma RPT level was not associated with a higher risk of SDR development (OR [95% CI]: 1.01 [1.00-1.02], p = 0.218).

The 3HP regimen is among the four regimens for LTBI that is recommended by the WHO and is also probably the most promising regimen because of its convenience, with only 12 doses requried. With its effectiveness well established, the major remaining concern regarding 3HP may be its AEs. Studies have estimated that 4.9% to 9.1% of those in close contact with patients with open TB and who received 3HP failed to complete the regimen because of the side effects.8,10 While on the 3HP regimen, SDRs have generally been linked with RPT, which has a well-known side effect: flu-like syndrome. Additionally, RPT is a newer agent, making it a possible contributor to SDRs given that a higher SDR rate was observed compared with other INH-containing regimens. Some scholars, however, have argued against this point. First, one study using the 3HP regimen demonstrated that rechallenge with RPT did not necessarily lead to SDRs. In the same study, rifapentine was better tolerated than isoniazid upon rechallenge. In another study involving 1200 mg of RPT once weekly as continuation therapy for active TB, no SDRs were linked with RPT. Finally, in a study of 162 pulmonary TB patients receiving RPT with a dosage of more than 15mg/kg daily, no patients developed SDRs. In literature review, we discovered that among reports describing an association between RPT and flu-like symptoms, RPT was commonly coadministered with INH. Furthermore, in cases describing an association between INH and flu-like symptoms, the associations were all proven with rechallenge.

Although a less well-known effect than that of RPT, INH can also lead to flu-like syndrome. Of the patients with active TB who were receiving INH, usually with a dose of 300 mg/day, 1%-9.8% developed flu-like syndrome. Case reports describing the association between INH and flu-like syndrome have also been published. In the 3HP regimen, INH dosage is 900 mg/week, and no data exist regarding the proportion of cases developing SDRs under a single INH dosage higher than this.

Some hypotheses could possibly explain the association between the high INH dose and SDRs during 3HP therapy. First, since INH could bind to key enzymes in cytokine pathways such as peroxidase, a high plasma level of INH may activate pathways which are not activated under usual dose of INH due to low binding affinity. Second, the high plasma INH level may interfere with or interact with rifapentine metabolite, resulting in SDRs. Rifapentine, however, did not affect INH pharmacokinetics. Interestingly, a study investigating drug-drug interactions between dolutegravir and once weekly RPT plus INH also revealed a higher INH AUC among those who develop toxicities and a higher INH level among two cases experiencing severe flu-like syndrome. In summary, our preliminary results and recent publications support the association between INH and SDR development because INH drug level, rather than RPT drug level, was discovered to be associated with SDR development, and the short duration and rapid resolution of symptoms in some cases may indicate that a rapidly metabolised drug was the causative agent.

Because rather high doses of INH and RPT are used in 3HP regimen and safety remains a big concern in preventive therapy and program roll-out, a new regimen, consisting of daily INH 300 mg and RPT 600 mg (450 mg if body weight <45.0 kg) for one month was compared with 9H in a large international, open-label RCT enrolling 3000 people living with HIV, so called the BRIEF TB trial. During follow-up, the incidence of active TB was 0.65 vs. 0.67 per 100 person-years in the 1HP and 9H groups, respectively, showing non-inferiority of the ultra-short course of preventive therapy. However, the incidence rate of targeted safety events (liver, gastrointestinal, neurologic, skin or hypersensitivity) was lower with the 1HP regimen (2.9% [2.2 - 3.9%]) than with 9H regimen (4.7% [3.6 - 6.0%], p = 0.016). Treatment completion rates were significantly higher among people taking 1HP (97 vs. 91%, p < 0.01). Because in the PREVENT TB trial the 3HP group had a significantly higher risk of adverse events than the 9H group, the preliminary results of the BRIEF TB trial suggest that by daily use of a relative small dose for both INH and RPT, the 1HP regimen, can be more tolerable than 3HP regimen.

In summary, there remains so many unknowns in rifapentine-based preventive therapy. Further study is necessary to consolidate the finding that INH may play a role in the development of SDRs during 3HP therapy, as well as to evaluate the completion rate and safety profile of 1HP therapy. Therefore, we conduct this prospective multicenter study to investigate whether risk of SDRs under 1HP is lower than that under 3HP.

Research Hypothesis: 1HP has a lower incidence rate of SDRs than 3HP

Objectives:

1. To compare the risk of SDRs in 1HP treatment and in 3HP treatment

2. To explore side effect profile of 1HP

Study Design

Conditions

Latent Tuberculosis Infection

Intervention

isoniazid and rifapentine

Status

Not yet recruiting

Source

National Taiwan University Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-09-24T05:27:37-0400

Clinical Trials [942 Associated Clinical Trials listed on BioPortfolio]

Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The inv...

Tuberculosis Clinical Trials Consortium Study 35

Hypotheses: Rifapentine (given as water-dispersible monolayer and/or fixed dose combination with isoniazid) dosing in HIV-infected and uninfected children ≤ 12 years of age with latent T...

Treatment of Latent Tuberculosis in Socially Marginalised Citizens

An open-label, randomised controlled trial comparing compliance to treatment for latent tuberculosis infection in socially marginalised citizens. Participants will be randomized to either ...

TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection

Compared to adults, children appear to require higher weight-based doses of rifapentine to acheive comparable drug levels. TBTC Study 26, a study of the effectiveness and tolerability of ...

Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection

The purpose of this study is to evaluate the pharmacokinetics, tolerability, and safety of once-weekly doses of rifapentine (RPT) and isoniazid (INH) in HIV-1-infected and HIV-1-uninfected...

PubMed Articles [7528 Associated PubMed Articles listed on BioPortfolio]

Isoniazid and Rifapentine Treatment Eradicates Persistent in Macaques.

Direct evidence for persistence of Mycobacterium tuberculosis (Mtb) during asymptomatic latent TB infection (LTBI) in humans is currently lacking. Moreover, while a 12-week regimen of once-weekly ison...

Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014.

In California, about 80% of tuberculosis disease is caused by untreated latent tuberculosis infection (LTBI), and the rate of LTBI is higher among incarcerated persons (16%) than among nonincarcerated...

Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers.

We investigated the adverse events (AEs) and treatment completion rates of a 3 month course of once-weekly isoniazid and rifapentine (3HP) in South Korean health care workers (HCWs) with latent tuberc...

Severe psoriasis entering remission after treatment for latent tuberculosis with isoniazid: Report of two cases.

Psoriasis is a multifactorial systemic disease with predominantly cutaneous manifestations. The role of tuberculosis infection in the pathogenesis of psoriasis has not been consistently proven. Curren...

Diagnosis and treatment of latent tuberculosis infection in patients undergoing treatment with immunobiologic agents: a four-year experience in an endemic area.

To describe the incidence of active tuberculosis and the occurrence of adverse events after isoniazid treatment in patients with latent tuberculosis infection (LTBI) who also had chronic inflammatory ...

Medical and Biotech [MESH] Definitions

The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.

Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.

Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Pathological conditions of the CARDIOVASCULAR SYSTEM caused by infection of MYCOBACTERIUM TUBERCULOSIS. Tuberculosis involvement may include the HEART; the BLOOD VESSELS; or the PERICARDIUM.

More From BioPortfolio on "Risk of SDRs Under 3HP and 1HP Regimen for LTBI"

Quick Search

Relevant Topics

Tuberculosis TB
Tuberculosis (TB) is an infectious disease caused by bacteria belonging to the Mycobacterium tuberculosis complex. Over nine million new cases of TB, and nearly two million deaths from TB, are estimated to occur around the world every year, and new inf...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Searches Linking to this Trial